Blocking CD28-B7 T-cell costimulation by systemic administration of CTLA4Ig, a fusion protein which binds B7 molecules on the surface of antigen-presenting cells, prevents rejection and induces tolerance in experimental acute allograft rejection models. We tested the effect of CTLA4Ig therapy on the process of chronic renal allograft rejection using an established experimental transplantation model. F344 kidneys were transplanted orthotopically into bilaterally nephrectomized LEW recipients. Control These data confirm that early blockade of the CD28-B7 T-cell costimulatory pathway prevents later development and evolution of chronic renal allograft rejection. Our results indicate that T-cell recognition ofalloantigen is a central event in initiating the process of chronic rejection, and that strategies targeted at blocking T-cell costimulation may prove to be a valuable clinical approach to preventing development of the process.The most common cause of human allograft failure after the first year posttransplant is the incompletely understood clinicopathological entity of chronic rejection (1-3). This process affects all types of solid organ grafts and is characterized morphologically by obliterative vasculopathy, interstitial fibrosis with variable degrees of mononuclear cell infiltration, and in the case of the kidney, glomerulosclerosis. Risk factors for its development include HLA mismatching, acute rejection, early graft ischemia, differences in donor and recipient size, adequacy of immunosuppression, and viral infections. The exact mechanisms responsible for its pathogenesis are unknown, although there is evidence that chronic graft dysfunction is mediated by both alloantigendependent as well as alloantigen-independent mechanisms (4). At this moment no specific therapies are available.T-cell recognition of alloantigens is the key initial event which ultimately results in allograft rejection (5, 6). T cells require two signals for full activation. The first signal is produced by engagement of the T-cell receptor with the foreign antigen presented as a peptide by antigen-presenting cells, thus providing antigenspecificity to the immune response. The second is a "costimulatory" signal mediated, among other interactions, by the T-cell accessory molecule CD28 interacting with the B7 family (B7-1 and B7-2) of molecules on antigen-presenting cells (7-9). In vitro, blockade of costimulatory signals inhibits T-cell activation and induces a state of antigen-specific unresponsiveness. In vivo, agents which block CD28-B7 costimulation, including the fusion protein CTLA4Ig or anti-B7 monoclonal antibodies, have been shown to inhibit the immune response in experimental models of acute transplant rejection and autoimmunity (10). In this study we have investigated the role of T-cell costimulatory blockade in an established model of chronic renal allograft rejection.
MATERIALS AND METHODSAnimals. Inbred 200-250 g male LEW rats (RT11) were used as graft recipients and F344 (RT1lvl) rats served as donors (Harlan-Spra...